Notification of major interest in shares. To download this report as a PDF file click here.
Bioventix plc
(“Bioventix” or the “Company”)
Posting of Annual Report and Notice of AGM
Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has today posted its Annual Report for the year ended 30 June 2024 together with a Notice of Annual General Meeting (“AGM”) and Form of Proxy to shareholders that have elected to receive documentation in hard copy format. The documents will also be available to download in PDF format below:
The Company’s AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on Thursday 5 December 2024 at 2.00pm.
For further information please contact:
Bioventix plc | Tel: 01252 728 001 | |
Peter Harrison | Chief Executive Officer | |
Cavendish Capital Markets Limited | Tel: 020 7220 0500 | |
Geoff Nash/Abigail Kelly | Corporate Finance | |
Nigel Birks/Harriet Ward | ECM |
Bioventix plc
(“Bioventix” or “the Company”)
Director Dealing
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 30 October 2024 that on 30 October 2024 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 300 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,330 pence per Ordinary Share (the “Purchase”).
Following the Purchase, Bruce Hiscock has a beneficial interest in 1,089 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
Bioventix plc Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
Cavendish Geoff Nash / Abigail Kelly Nigel Birks / Harriet Ward |
Corporate Finance ECM |
Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
a) |
Name |
Bruce Hiscock |
2. |
Reason for the Notification |
|
a) |
Position/status |
Chief Financial Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
Bioventix Plc |
b) |
LEI |
213800225MHX7LZQY108 |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 5 pence each |
Identification code |
GB00B4QVDF07 |
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
c) |
Price(s) and volume(s) |
300 Ordinary Shares 3,330 pence |
d) |
Aggregated information:
· Aggregated volume
· Price |
Purchase of 300 Ordinary Shares at 3,330 pence each |
e) |
Date of the transaction |
30 October 2024 |
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
Director’s report and financial statements for the year ended 30th June 2024.
To download this report as a PDF file click here.
Notification of major interest in shares. To download this report as a PDF file click here.
Polycylic Aromatic Hydrocarbons (PAHs) are produced during the incomplete burning of organic materials. PAH sources include vehicle exhaust, tobacco smoke and waste incineration. Environmental and occupational exposures to PAHs are known to occur. Cancer is a significant endpoint of PAH exposure and several occupations associated with high PAH exposure have been classified by IARC as carcinogenic to humans (Group 1).
Pyrene is a common component of PAH mixtures and metabolism of pyrene leads to the excretion of 1-hydroxypyrene glucuronide (1-OHPyrG) in urine. Laboratory measurement of urinary 1-OHPyrG is employed in occupational and environmental biomonitoring programmes. The production of an anti-1-OHPyrG monoclonal antibody would allow the development of a PAH biomonitoring ELISA facilitating large scale laboratory screening and routine testing.
The development of a lateral flow immunoassay and the production of a field test (point of use test) would greatly increase the value of biomonitoring. A novel Lateral Flow has been developed which employs an anti-1-OHPyrG sheep monoclonal antibody (Mab) to capture the PAH metabolite. The captured metabolite is visualised through a second Mab raised against the Mab-1-OHPyrG immune complex. This sandwich assay provides a positive correlation between the assay signal and biomarker concentration.
A Smartphone camera allows signal measurement and a carefully considered ‘app’ provides result interpretation and data analysis. Results are provided in an exposed/not-exposed format. Performance of the lateral flow was confirmed through a comparative study and field trial. The development of a lateral flow test provides “realtime” analysis to occupational health professionals. On-site screening allows the immediate confirmation of safe working practice, provides immediate reassurance to those involved in potentially hazardous activities and greatly increases the efficacy of biomonitoring.
Bioventix plc
(“Bioventix” or “the Company”)
Director Dealing
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that on 29 April 2024 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 11 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 4,452 pence per Ordinary Share (the “Purchase”). The Ordinary Shares were purchased under a dividend reinvestment plan (“DRIP”).
Following the Purchase, Bruce Hiscock has a beneficial interest in 789 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
Bioventix plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
Cavendish
Geoff Nash / Simon Hicks Nigel Birks / Harriet Ward |
Corporate Finance ECM |
Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Bruce Hiscock |
2. | Reason for the Notification | |
a) | Position/status | Chief Financial Officer |
b) | Initial notification/Amendment | Initial notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Bioventix Plc |
b) | LEI | 213800225MHX7LZQY108 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 5 pence each |
Identification code | GB00B4QVDF07 | |
b) | Nature of the transaction | Purchase of Ordinary Shares |
c) | Price(s) and volume(s) | 11 Ordinary Shares
4,552 pence |
d) | Aggregated information:
· Aggregated volume
· Price |
Purchase of 11 Ordinary Shares at 4,452 pence each |
e) | Date of the transaction | 29 April 2024 |
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
Objectives
To investigate whether circulating acute-phase brain-derived tau (BD-tau) is associated with functional outcome after ischemic stroke.
Methods
Plasma tau was measured by a novel assay that selectively quantifies BD-tau in the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS), which includes adult cases with ischemic stroke and controls younger than 70 years, and in an independent cohort of adult cases of all ages (SAHLSIS2). Associations with unfavorable 3-month functional outcome (modified Rankin scale score >2) were analyzed by logistic regression. Various stratified and sensitivity analyses were performed, for example, by age, stroke severity, recanalization therapy, and etiologic subtype.
Results
This study included 454 and 364 cases from the SAHLSIS and SAHLSIS2, with a median age of 58 and 68 years, respectively. Higher acute BD-tau concentrations were significantly associated with increased odds of unfavorable outcome after adjustment for age, sex, day of blood draw, and stroke severity (NIH stroke scale score) in both cohorts (OR per doubling of BD-tau: 2.9 [95% CI 2.2–3.7], P = 1 × 10−15 and 1.8 [1.5–2.2], P = 7 × 10−9, respectively). The association was consistent in the different stratified and sensitivity analyses.
Discussion
BD-tau is a promising blood-based biomarker of ischemic stroke outcomes, and future studies in larger cohorts are warranted.
Interim Report and Financial Statements for the 6 months to 31 December 2023
To download this report as a PDF file click here.